---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000130"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:36:03.044455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M

## Summary
- Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).
- Full-year 2023 total revenue guidance tightened to $155-165M from $145-165M.
- Received $6M milestone payment from Amgen for subcutaneous TEPEZZA formulation success.
- Company reaffirms cash flow breakeven in Q4 2023; net cash outflow H2 expected ~$11-16M.
- Q3 2023 earnings call scheduled for November 9, 2023 at 8:30 a.m. ET.

## SEC filing metadata
- accession: 0001867096-23-000130
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/0001867096-23-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/xers-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000130
- JSON: https://secwatch.observer/filing/0001867096-23-000130.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.